MX2021000998A - Oligonucleotidos antisentido de acetil-coa carboxilasa2. - Google Patents
Oligonucleotidos antisentido de acetil-coa carboxilasa2.Info
- Publication number
- MX2021000998A MX2021000998A MX2021000998A MX2021000998A MX2021000998A MX 2021000998 A MX2021000998 A MX 2021000998A MX 2021000998 A MX2021000998 A MX 2021000998A MX 2021000998 A MX2021000998 A MX 2021000998A MX 2021000998 A MX2021000998 A MX 2021000998A
- Authority
- MX
- Mexico
- Prior art keywords
- coa
- acetyl
- antisense oligonucleotides
- human acc2
- mrna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/53—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y604/00—Ligases forming carbon-carbon bonds (6.4)
- C12Y604/01—Ligases forming carbon-carbon bonds (6.4.1)
- C12Y604/01002—Acetyl-CoA carboxylase (6.4.1.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona el derivado de ácido nucleico peptídico que se dirige al sitio de corte y empalme 5' del "exón 12" humano de ACC2. Los derivados de ácido nucleico peptídico en la presente invención inducen en gran medida variantes de empalme del ARNm de ACC2 humano en la célula y son muy útiles para tratar afecciones o trastornos del envejecimiento de la piel asociados con la proteína ACC2 humana.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180095124A KR102304280B1 (ko) | 2018-08-14 | 2018-08-14 | 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드 |
PCT/KR2019/009697 WO2020036353A1 (en) | 2018-08-14 | 2019-08-05 | Acetyl-coa carboxylase2 antisense oligonucleotides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021000998A true MX2021000998A (es) | 2021-06-23 |
Family
ID=69525636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021000998A MX2021000998A (es) | 2018-08-14 | 2019-08-05 | Oligonucleotidos antisentido de acetil-coa carboxilasa2. |
Country Status (13)
Country | Link |
---|---|
US (1) | US11739124B2 (es) |
EP (1) | EP3837274A4 (es) |
JP (2) | JP2021534146A (es) |
KR (1) | KR102304280B1 (es) |
CN (1) | CN112566922B (es) |
AR (1) | AR115955A1 (es) |
AU (1) | AU2019320670B2 (es) |
BR (1) | BR112020026541A2 (es) |
CA (1) | CA3104658A1 (es) |
MX (1) | MX2021000998A (es) |
SG (1) | SG11202012829RA (es) |
TW (1) | TWI826490B (es) |
WO (1) | WO2020036353A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102304280B1 (ko) | 2018-08-14 | 2021-09-23 | 올리패스 주식회사 | 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6133444A (en) | 1993-12-22 | 2000-10-17 | Perseptive Biosystems, Inc. | Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions |
US6617422B1 (en) | 1997-05-23 | 2003-09-09 | Peter Nielsen | Peptide nucleic acid monomers and oligomers |
US20030105044A1 (en) | 2001-10-17 | 2003-06-05 | Isis Pharmaceuticals Inc. | Antisense modulation of matrix metalloproteinase 1 expression |
US20040215006A1 (en) | 2003-04-25 | 2004-10-28 | Isis Pharmaceuticals Inc. | Modulation of tyrosinase expression |
GB0415196D0 (en) * | 2004-07-07 | 2004-08-11 | Astrazeneca Ab | Polypeptide |
US7211423B2 (en) * | 2004-07-23 | 2007-05-01 | Bristol-Myers Squibb Co. | Acetyl CoA carboxylase 2 sequences and methods |
AU2006235451A1 (en) * | 2005-04-08 | 2006-10-19 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to acetyl-CoA carboxylases |
BE1017127A6 (nl) | 2006-03-24 | 2008-03-04 | Hyfte Luc J R Van | Scharnierende bevestiging van een paddelroerwerk. |
JP2010075639A (ja) * | 2007-10-19 | 2010-04-08 | Shiseido Co Ltd | 顔面及び頸部の皮膚状態を改善する美容方法及び装置 |
KR20090098710A (ko) | 2008-03-14 | 2009-09-17 | 주식회사 씨티아이바이오 | 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체 |
KR20110112381A (ko) | 2008-12-31 | 2011-10-12 | 레반스 테라퓨틱스, 아이엔씨. | 색소 과다 침착의 치료용 조성물 및 치료 방법 |
WO2010123983A1 (en) | 2009-04-21 | 2010-10-28 | Yale University | Compostions and methods for targeted gene therapy |
KR20120073536A (ko) * | 2010-12-27 | 2012-07-05 | 주식회사 파나진 | 다중전하를 갖는 pna |
WO2013112548A1 (en) | 2012-01-23 | 2013-08-01 | University Of South Florida | Gamma-aapeptides with potent and broad-spectrum antimicrobial activity |
US20140314697A1 (en) | 2013-04-18 | 2014-10-23 | Corum Inc. | Method for Inhibiting Inflammation and Reducing Melanophilin Expression with Glycine Derivatives And the Composition Thereof |
KR101809209B1 (ko) * | 2016-05-31 | 2017-12-15 | 주식회사 올리패스코스메슈티컬즈 | 두피의 건강 개선을 위한 화장료 조성물 및 이의 제조방법 |
US20190345202A1 (en) * | 2016-08-08 | 2019-11-14 | Olipass Corporation | Androgen receptor antisense oligonucleotides |
EP3512870B1 (en) | 2016-09-16 | 2022-08-03 | Olipass Corporation | Scn9a antisense oligonucleotides |
RU2753517C2 (ru) | 2016-10-11 | 2021-08-17 | Олипасс Корпорейшн | Антисмысловые олигонуклеотиды к hif-1-альфа |
US20190337987A1 (en) * | 2016-12-30 | 2019-11-07 | Olipass Corporation | Exon skipping by peptide nucleic acid derivatives |
JP7503903B2 (ja) * | 2017-01-06 | 2024-06-21 | オリパス コーポレーション | Snap25アンチセンスオリゴヌクレオチド |
RU2762293C2 (ru) | 2017-01-24 | 2021-12-17 | Олипасс Корпорейшн | Антисмысловое для scn9a обезболивающее средство |
WO2019022434A1 (en) | 2017-07-24 | 2019-01-31 | Olipass Corporation | ANTISENSE OLIGONUCLEOTIDES OF TYROSINASE |
TWI832851B (zh) | 2018-05-18 | 2024-02-21 | 韓商奧利通公司 | 基質金屬蛋白酶-1之反義寡核苷酸 |
KR102304280B1 (ko) | 2018-08-14 | 2021-09-23 | 올리패스 주식회사 | 아세틸코에이카복실라제2 안티센스 올리고뉴클레오티드 |
JP2022541896A (ja) | 2019-07-18 | 2022-09-28 | オリパス コーポレーション | メラノフィリンアンチセンスオリゴヌクレオチド |
-
2018
- 2018-08-14 KR KR1020180095124A patent/KR102304280B1/ko active IP Right Grant
-
2019
- 2019-07-23 TW TW108126009A patent/TWI826490B/zh active
- 2019-08-05 CN CN201980053079.5A patent/CN112566922B/zh active Active
- 2019-08-05 SG SG11202012829RA patent/SG11202012829RA/en unknown
- 2019-08-05 US US17/266,763 patent/US11739124B2/en active Active
- 2019-08-05 BR BR112020026541-1A patent/BR112020026541A2/pt unknown
- 2019-08-05 CA CA3104658A patent/CA3104658A1/en active Pending
- 2019-08-05 WO PCT/KR2019/009697 patent/WO2020036353A1/en unknown
- 2019-08-05 MX MX2021000998A patent/MX2021000998A/es unknown
- 2019-08-05 EP EP19850610.7A patent/EP3837274A4/en active Pending
- 2019-08-05 JP JP2021507611A patent/JP2021534146A/ja active Pending
- 2019-08-05 AU AU2019320670A patent/AU2019320670B2/en active Active
- 2019-08-14 AR ARP190102319A patent/AR115955A1/es unknown
-
2023
- 2023-12-26 JP JP2023218786A patent/JP2024038106A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019320670A1 (en) | 2021-02-11 |
US11739124B2 (en) | 2023-08-29 |
WO2020036353A1 (en) | 2020-02-20 |
EP3837274A1 (en) | 2021-06-23 |
TW202022115A (zh) | 2020-06-16 |
CN112566922A (zh) | 2021-03-26 |
EP3837274A4 (en) | 2022-05-18 |
CN112566922B (zh) | 2024-09-13 |
JP2021534146A (ja) | 2021-12-09 |
AU2019320670B2 (en) | 2024-04-11 |
KR102304280B1 (ko) | 2021-09-23 |
KR20200019509A (ko) | 2020-02-24 |
TWI826490B (zh) | 2023-12-21 |
AR115955A1 (es) | 2021-03-17 |
SG11202012829RA (en) | 2021-02-25 |
JP2024038106A (ja) | 2024-03-19 |
US20210363190A1 (en) | 2021-11-25 |
BR112020026541A2 (pt) | 2021-04-06 |
CA3104658A1 (en) | 2020-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ747685A (en) | Oligonucleotide analogues targeting human lmna | |
BR112017016068A2 (pt) | composições para modulação de expressão de c9orf72 | |
EP3700570A4 (en) | ANTISENSE OLIGOMERS FOR THE TREATMENT OF CONDITIONS AND DISEASES BASED ON THE DECLINE OF NON-SENSE MEDIATION RNA | |
EP4166667A3 (en) | Compositions for modulating c9orf72 expression | |
PH12017550069A1 (en) | Tau antisense oligomers and uses thereof | |
EP3862362A3 (en) | Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression | |
WO2013086444A3 (en) | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna | |
BR112017013597A2 (pt) | molécula de ácido nucleico, composição farmacêutica, vetor ou célula, e, método para tratamento de uma doença. | |
MX2019008445A (es) | Calmante de dolor scn9a antisentido. | |
BR112022002691A2 (pt) | Construtos de vesícula-aso extracelular visando stat6 | |
BR112019002387A2 (pt) | oligonucleotídeos antissenso de receptor de andrógeno | |
WO2011090741A3 (en) | TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63 | |
AR107579A1 (es) | Composiciones y métodos para disminuir la expresión de tau | |
MX2020007439A (es) | Oligonucleotidos antisentido que actuan sobre alfa-sinucleina y usos de estos. | |
SA520412423B1 (ar) | أوليجونيوكليوتيدات مضادة للحس تستهدف ألفا- سينيوكلين واستخداماتها | |
WO2017151860A8 (en) | Human kynureninase enzyme variants having improved pharmacological properties | |
MX2021000998A (es) | Oligonucleotidos antisentido de acetil-coa carboxilasa2. | |
Zhu et al. | Regulation of acetylcholinesterase expression by calcium signaling during calcium ionophore A23187-and thapsigargin-induced apoptosis | |
EA201792406A1 (ru) | Антисмысловые олигонуклеотиды для лечения дистрофического буллезного эпидермолиза | |
MX2020009836A (es) | Oligonucleotidos antisentido de metaloproteinasa-1 de matriz. | |
MX2023009151A (es) | Composiciones para el tratamiento de afecciones y enfermedades asociadas con la expresion de policistina. | |
MX2019007903A (es) | Oligonucleotidos antisentido de proteina asociada a sinaptosoma de 25 kda (snap25). | |
MX2020008533A (es) | Terapia con oligonucleotidos para la enfermedad de wilson. | |
Davidson et al. | A5. 18 BMP2 requires TGF-BETA to induce osteophytes during experimental osteoarthritis | |
Gauthier-Rouvière et al. | RhoA leads to up-regulation and relocalization of utrophin in muscle fibers |